Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089433 | 0.79 | NPC1 (0.39) | NOTUMRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL2092720 | 0.79 | ENPP3 (0.46) | NOTUMMETAP2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2751647 | 0.79 | KMO (0.33) | — | |
| SCHEMBL2096696 | 0.79 | AHR (0.46) | NOTUMRAB9ANPC1LMNA | |
| SCHEMBL102449 | 0.78 | RAB9A (0.41) | NOTUMMETAP2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2098115 | 0.75 | KIF11 (0.44) | NOTUMLTA4HRAB9ANPC1KDM4E | |
| SCHEMBL2752347 | 0.73 | HSP90AA1 (0.47) | RAB9ANPC1SMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL2753481 | 0.73 | IDO1 (0.45) | RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7387155 | 0.71 | ALDH1A1 (0.35) | MAPTCYP1A2 | |
| SCHEMBL9488955 | 0.71 | NPC1 (0.40) | NOTUMRAB9ANPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-18 | — | — | US | disclosed |
| EP-2999699-B1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY SCIENCE TECH & RES (SG) | 2020-04-29 | — | — | EP | disclosed |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-11-12 | — | — | US | disclosed |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-06-21 | — | — | US | disclosed |
| US-9926320-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-27 | — | — | US | disclosed |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-11-23 | — | — | US | disclosed |
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-31 | — | — | US | disclosed |
| EP-2999699-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | Agency For Science, Technology And Research (SG) | 2016-03-30 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| CN-1314899-A | Retinoid-associated receptor regulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090386-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | NOTUM 4296/4885METAP2 3865/4885LTA4H 2505/4885 |
| US-20170334912-A1 | Purine Diones As Wnt Pathway Modulators | WNT1, WNT3A, CTNNB1 | NOTUM 4296/4885METAP2 3865/4885LTA4H 2505/4885 |
| US-10472360-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | NOTUM 4296/4885METAP2 3865/4885LTA4H 2505/4885 |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | NOTUM 4491/4885METAP2 3961/4885LTA4H 2648/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NOTUM 4043/4885METAP2 4360/4885LTA4H 3093/4885 |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | NOTUM 4296/4885METAP2 3865/4885LTA4H 2505/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | NOTUM 4491/4885METAP2 3961/4885LTA4H 2648/4885 |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | NOTUM 4296/4885METAP2 3865/4885LTA4H 2505/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | NOTUM 4491/4885METAP2 3961/4885LTA4H 2648/4885 |
| US-20180170932-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | NOTUM 4296/4885METAP2 3865/4885LTA4H 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.